LifeSensors
LifeSensors Inc. is a biotech company dedicated to advancing research and drug discovery in the fields of ubiquitin proteasome system, PROTACs, molecular glues, and neurodegeneration diagnostics. They collaborate with pharma and biotech partners, providing innovative tools, assays, products, and services to facilitate understanding and targeting of the ubiquitin system for therapeutic development.
Industries
Nr. of Employees
small (1-50)
LifeSensors
271 Great Valley Parkway Malvern, PA 19355
Patents
Products
Bead‑immobilized tandem ubiquitin‑binding affinity matrices (pan- and linkage‑selective)
Bead-immobilized tandem ubiquitin-binding reagents for enrichment and pulldown of polyubiquitinated proteins, available in pan-selective and linkage‑selective formats and in agarose and magnetic bead presentations.
Internally‑quenched di‑ubiquitin FRET substrates
Linkage-defined di‑ubiquitin substrates configured as internally-quenched FRET pairs to report isopeptidase (DUB) cleavage by fluorescence increase; panels available for multiple linkages to support specificity and kinetic studies.
High-throughput plate-based assay kits (colorimetric and chemiluminescent)
Plate kits and consumables configured for high‑throughput evaluation of ubiquitination and degradation activity, available in colorimetric and chemiluminescent readouts and compatible with HTS workflows.
SUMO‑family expression kits and vectors
Kits containing SUMO plasmids, proteases, control proteins and detection reagents to support expression and purification workflows optimized for difficult-to-express proteins across common host systems.
Antibodies for ubiquitin- and SUMO-pathway proteins
Antibodies for detection of SUMO tags, deSUMOylases, deubiquitinases and other ubiquitin-pathway proteins to support expression checks, protease cleavage validation and immunodetection workflows.
Bead‑immobilized tandem ubiquitin‑binding affinity matrices (pan- and linkage‑selective)
Bead-immobilized tandem ubiquitin-binding reagents for enrichment and pulldown of polyubiquitinated proteins, available in pan-selective and linkage‑selective formats and in agarose and magnetic bead presentations.
Internally‑quenched di‑ubiquitin FRET substrates
Linkage-defined di‑ubiquitin substrates configured as internally-quenched FRET pairs to report isopeptidase (DUB) cleavage by fluorescence increase; panels available for multiple linkages to support specificity and kinetic studies.
High-throughput plate-based assay kits (colorimetric and chemiluminescent)
Plate kits and consumables configured for high‑throughput evaluation of ubiquitination and degradation activity, available in colorimetric and chemiluminescent readouts and compatible with HTS workflows.
SUMO‑family expression kits and vectors
Kits containing SUMO plasmids, proteases, control proteins and detection reagents to support expression and purification workflows optimized for difficult-to-express proteins across common host systems.
Antibodies for ubiquitin- and SUMO-pathway proteins
Antibodies for detection of SUMO tags, deSUMOylases, deubiquitinases and other ubiquitin-pathway proteins to support expression checks, protease cleavage validation and immunodetection workflows.
Services
Contract assay development and execution to measure ubiquitination, ternary complex formation and target degradation for PROTAC and molecular-glue programs, using in vitro and cell-based formats and enabling target validation.
Biochemical and cell-based screening services for E3 ligase activity and ligase-centric ligand discovery, combining gel-based assays, thermal shift, SPR and substrate ubiquitination assays.
Enzymatic assay development and high-throughput screening for deubiquitinases using fluorogenic substrates and internally-quenched di‑ubiquitin panels to determine linkage specificity and kinetics.
End-to-end proteomics service combining ubiquitin-affinity pulldown with LC‑MS/MS and bioinformatic analysis to identify and quantify ubiquitinated proteins and modification sites.
Expression system development and protein production using SUMO-family fusion tags across bacterial, yeast, insect and mammalian hosts, with supporting reagents and cleavage proteases.
Custom development of biomarker and diagnostic assays focused on neurodegenerative disease applications, translating biochemical activity to cellular and animal models to support diagnostic strategy development.
Contract assay development and execution to measure ubiquitination, ternary complex formation and target degradation for PROTAC and molecular-glue programs, using in vitro and cell-based formats and enabling target validation.
Biochemical and cell-based screening services for E3 ligase activity and ligase-centric ligand discovery, combining gel-based assays, thermal shift, SPR and substrate ubiquitination assays.
Enzymatic assay development and high-throughput screening for deubiquitinases using fluorogenic substrates and internally-quenched di‑ubiquitin panels to determine linkage specificity and kinetics.
End-to-end proteomics service combining ubiquitin-affinity pulldown with LC‑MS/MS and bioinformatic analysis to identify and quantify ubiquitinated proteins and modification sites.
Expression system development and protein production using SUMO-family fusion tags across bacterial, yeast, insect and mammalian hosts, with supporting reagents and cleavage proteases.
Custom development of biomarker and diagnostic assays focused on neurodegenerative disease applications, translating biochemical activity to cellular and animal models to support diagnostic strategy development.
Expertise Areas
- Targeted protein degradation (PROTAC and molecular-glue discovery)
- Ubiquitin–proteasome system biology
- E3 ligase profiling and ligand discovery
- Deubiquitinase assay development and screening
Key Technologies
- Affinity enrichment with tandem ubiquitin-binding domains
- Quantitative LC‑MS/MS proteomics
- Internally-quenched di‑ubiquitin FRET substrates
- Fluorogenic ubiquitin-based enzymatic assays
News & Updates
LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTACs, molecular glues, and neurodegeneration diagnostics will disclose direct methods to detect PROTAC & molecular glue mediated ubiquitination drug targets at BIO this year in Boston, MA, June 5-8, 2023.
Devastating Origins In the late 1950s and early 1960s, pregnant women who experienced nausea and morning sickness were prescribed thalidomide, a sedative drug meant to treat these symptoms. In early 1960, it quickly became evident that there was a link between the thousands of infants born with severe birth defects and thalidomide.
Hijacking the natural mechanism of the Ubiquitin Proteasome System (UPS) is emerging as a powerful medium in drug discovery through which Dr. Kadimisetty uses “TUBEs” as ubiquitin-binding entities to monitor PROTAC-mediated poly-ubiquitination of target proteins. The technology described wherein is a direct way to evaluate and discover PROTAC and molecular glue targets for use in drug discovery.
Discovering Unique Ubiquitin E3 Ligase Ligands to Unlock Targeted Protein degradation Gauthami Jalagadugula, Alexandra Russell1+, Kenneth Wallace1+, Janelle Pedroza and Abdul Haseeb1 * Introduction PROteolytic TArgeting Chimeras (PROTACs) have emerged as new class of drugs to target “undruggable” proteome. The human genome encodes ~ 600 E3 ligases that differentially expressed across various tissues. Only a few E3 ligases have been utilized to date for PROTAC applications.
MALVERN, Pa., October 26, 2023 — LifeSensors, Inc., a leading innovator in protein degradation technologies, has been invited to speak at the 6th Annual Targeted Protein Degradation Summit 2023 in Boston, Massachusetts. The event will take place from October 30-November 2 at Westin Copley Place, Boston. LifeSensors will be exhibiting, and Dr. Karteek Kadimisetty will present new information and answer questions regarding PROTACs, molecular glues, and the future of drug discovery.
Malvern, PA, October 18, 2023 — LifeSensors Inc., a biotech company targeting the ubiquitin proteasome system for drug discovery and diagnostic markers, has received funding from the National Institute on Aging and National Institute of General Medicine. The funding, amounting to $5.53 million, supports the development of PROTAC drug discovery technologies.
LifeSensors Inc., a Biotech and Drug Discovery Company focused on PROTACs, molecular glues, and neurodegeneration diagnostics will disclose direct methods to detect PROTAC & molecular glue mediated ubiquitination drug targets at BIO this year in Boston, MA, June 5-8, 2023.
Devastating Origins In the late 1950s and early 1960s, pregnant women who experienced nausea and morning sickness were prescribed thalidomide, a sedative drug meant to treat these symptoms. In early 1960, it quickly became evident that there was a link between the thousands of infants born with severe birth defects and thalidomide.
Hijacking the natural mechanism of the Ubiquitin Proteasome System (UPS) is emerging as a powerful medium in drug discovery through which Dr. Kadimisetty uses “TUBEs” as ubiquitin-binding entities to monitor PROTAC-mediated poly-ubiquitination of target proteins. The technology described wherein is a direct way to evaluate and discover PROTAC and molecular glue targets for use in drug discovery.
Discovering Unique Ubiquitin E3 Ligase Ligands to Unlock Targeted Protein degradation Gauthami Jalagadugula, Alexandra Russell1+, Kenneth Wallace1+, Janelle Pedroza and Abdul Haseeb1 * Introduction PROteolytic TArgeting Chimeras (PROTACs) have emerged as new class of drugs to target “undruggable” proteome. The human genome encodes ~ 600 E3 ligases that differentially expressed across various tissues. Only a few E3 ligases have been utilized to date for PROTAC applications.
MALVERN, Pa., October 26, 2023 — LifeSensors, Inc., a leading innovator in protein degradation technologies, has been invited to speak at the 6th Annual Targeted Protein Degradation Summit 2023 in Boston, Massachusetts. The event will take place from October 30-November 2 at Westin Copley Place, Boston. LifeSensors will be exhibiting, and Dr. Karteek Kadimisetty will present new information and answer questions regarding PROTACs, molecular glues, and the future of drug discovery.
Malvern, PA, October 18, 2023 — LifeSensors Inc., a biotech company targeting the ubiquitin proteasome system for drug discovery and diagnostic markers, has received funding from the National Institute on Aging and National Institute of General Medicine. The funding, amounting to $5.53 million, supports the development of PROTAC drug discovery technologies.